Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study
Advanced high-grade serous ovarian carcinoma is a serious malignant neoplasm with a late diagnosis and high mortality rate. Even when treated with standard therapy, such as surgery followed by carboplatin and paclitaxel chemotherapy, the prognosis remains unfavorable. Immunotherapy is a treatment al...
Main Authors: | Ana Paula Dergham, Caroline Busatta Vaz de Paula, Seigo Nagashima, Márcia Olandoski, Lucia de Noronha, Vanessa Santos Sotomaior |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/13/7/1045 |
Similar Items
-
EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes
by: Simona De Rosa, et al.
Published: (2018-04-01) -
PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
by: YunYi Du, et al.
Published: (2022-11-01) -
Simultaneous p53 and KRAS mutation in a high-grade serous carcinoma with deceptive appearance of a low-grade carcinoma. A case report
by: Shivali Marketkar, et al.
Published: (2023-06-01) -
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
by: Chiara M. Biatta, et al.
Published: (2023-08-01) -
Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency
by: Nuran Sungu, et al.
Published: (2023-10-01)